Skip to main content

Table 1 Patient demographics between groups

From: Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Variable

CPB (n = 124)

CPA (n = 122)

p-value

Age (years)

62.1 ± 7.59

62.2 ± 6.84

0.183a

BMI

24.5 ± 5.31

25.6 ± 6.19

0.102a

Haemoglobin < 11 g/dLc, n (%)

36 (29.0)

32 (26.2)

0.624b

Histology, n (%)

  

0.439b

 Squamous

79 (63.7)

72 (59.0)

 

 Adenocarcinoma

34 (27.4)

37 (30.3)

 

 Adenosquamous

11 (8.9)

13 (10.7)

 

IVB cervical cancer, n (%)

  

0.533b

 Asymptomatic CNS metastasis

45 (36.3)

49 (40.2)

 

 Without CNS metastasis

79 (63.7)

73 (59.8)

 

Duration of drug (months)

17.8 ± 7.46

17.4 ± 7.63

0.219a

ECOG status, n (%)

  

0.663b

 0d

46 (37.1)

42 (34.4)

 

 1e

78 (62.9)

80 (65.6)

 

GOG statusf, n (%)

  

0.672b

 0f

49 (39.5)

45 (36.9)

 

 1g

75 (60.5)

77 (63.1)

 

No. of metastatic sites, n (%)

  

0.445b

 3

38 (30.6)

30 (27.8)

 

  > 3

71 (57.3)

78 (62.0)

 

 Unknown

15 (12.1)

14 (10.2)

 
  1. aAnalysed using an independent samples t-test; bAnalysed using the Mann-Whitney U test;
  2. cHaemoglobin level was calculated one week before the start of CPB or CPA; 0d, Fully active, able to carry on all pre-disease performance without restriction; 1e, Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work; 0f: fully active; 1g: restricted in physically strenuous activities, but ambulatory. CPB cisplatin-paclitaxel chemotherapy plus bevacizumab, CPA cisplatin-paclitaxel chemotherapy alone, BMI body mass index, CNS central nervous system, ECOG Eastern Collaborative Oncology Group, GOG Gynecologic Oncology Group